Emergent BioSolutions Inc.

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 TTM
Total Revenue $488.8m
$560.9m +14.75%
$782.4m +39.50%
$1.1b +41.36%
$1.6b +40.63%
$1.8b +15.26%
$1.1b -37.66%
$1.0b -6.10%
$1.0b -0.54%
$742.9m -28.81%
$742.3m -0.08%
Cost of Revenue $131.3m
$195.7m +49.07%
$322.3m +64.68%
$433.5m +34.50%
$524.0m +20.88%
$748.1m +42.77%
$693.1m -7.35%
$705.4m +1.77%
$681.3m -3.42%
$326.2m -52.12%
$339.9m +4.20%
Gross Profit $357.5m
$365.2m +2.14%
$460.1m +26.00%
$672.5m +46.16%
$1.0b +53.37%
$1.0b +1.28%
$383.0m -63.34%
$317.6m -17.08%
$362.3m +14.07%
$416.7m +15.02%
$402.4m -3.43%
Research and Development Expense $108.3m $97.4m $142.8m $226.2m $234.5m $234.0m $188.3m $111.4m $70.7m $53.2m $45.3m
Selling, General and Administrative Expense $143.7m $143.5m $202.5m $273.5m $303.3m $348.4m $339.5m $368.4m $308.0m $186.1m $181.2m
Amortization of Intangible Assets $6.9m $8.6m $25.0m $58.7m $59.8m $58.5m $59.9m $65.6m $65.1m $65.1m
Operating Lease, Lease Income $30.5m $62.1m
Operating Costs and Expenses $1.1b $1.4b $1.3b $1.8b $1.2b $642.8m
Operating Expenses $692.6m $991.9m $604.8m
Operating Income (Loss) $105.5m
$124.3m +17.78%
$89.8m -27.75%
$114.1m +27.06%
$433.8m +280.19%
$352.6m -18.72%
($170.0m) -148.21%
($726.4m) -327.29%
($108.7m) +85.04%
$100.1m +192.09%
$137.5m +37.36%
Interest Expense $7.6m $6.6m $9.9m $38.4m $31.3m $34.5m $37.3m $87.9m $50.9m
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement ($1.0m) $0 $400k $0
Other Nonoperating Income (Expense) $263k ($815k) $1.6m $1.7m $4.7m ($3.7m) ($11.7m) $8.9m $12.5m $54.2m
Interest Expense (non-operating) $71.0m $59.3m $50.9m
Income (Loss) from Continuing Operations before Income Taxes, Domestic $63.3m $80.7m $71.0m $63.9m $362.0m $112.0m ($442.6m) ($805.1m) ($355.5m) ($4.7m) ($146.0m)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $314.4m ($219.0m) ($731.2m) ($142.9m) $82.8m ($146.0m)
Current Income Tax Expense (Benefit) $32.6m $32.8m $10.2m $24.0m $104.5m $39.6m $26.3m $36.6m $53.2m $34.1m $30.8m
Income Tax Expense (Benefit) $36.7m $36.0m $18.8m $22.9m $102.1m $83.5m ($7.4m) $29.3m $47.7m $30.2m $30.8m
Net Income (Loss) Attributable to Parent $51.8m
$82.6m +59.52%
$62.7m -24.09%
$54.5m -13.08%
$305.1m +459.82%
$230.9m -24.32%
($211.6m) -191.64%
($760.5m) -259.40%
($190.6m) +74.94%
$52.6m +127.60%
($176.8m) -436.12%
Earnings Per Share, Basic $1.29 $1.98 $1.25 $1.06 $5.79 $4.32 ($4.22) ($14.85) ($3.60) $0.98 ($3.40)
Earnings Per Share, Diluted $1.13 $1.71 $1.22 $1.04 $5.67 $4.27 ($4.22) ($14.85) ($3.60) $0.93 ($3.41)
Income (Loss) from Continuing Operations, Per Basic Share $2 $2 $1
Income (Loss) from Continuing Operations, Per Diluted Share $1 $2 $1
Weighted Average Number of Shares Outstanding, Basic 40.2m 41.8m 50.1m 51.5m 52.7m 53.5m 50.1m 51.2m 53.0m 53.5m 52.2m
Weighted Average Number of Shares Outstanding, Diluted 49.3m 50.3m 51.4m 52.4m 53.8m 54.1m 50.1m 51.2m 53.0m 56.7m 54.2m
Additional Financial Items
Goodwill, Impairment Loss $0 $0 $41.7m $6.7m $218.2m $0 $0 $203.5m
Income (Loss) Attributable to Parent, before Tax $77.4m $407.2m $314.4m ($218.6m) ($731.2m) ($142.9m) $82.8m
Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest $62.5m $82.6m $62.7m
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest ($10.7m) $0 $0

Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.